

Special Issue

Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)

Message from the Guest Editors

ECB 2021 will present the latest research related to all aspects of research on human health and disease, the discovery and characterisation of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics of interest include but are not limited to: nanomedicine and precision medicine; nutraceuticals, nano nutraceuticals, and nano pharmaceuticals; cancer therapeutics; metal-based therapeutics in preclinical and clinical developments; oncolytic virus-mediated immunotherapy; neuroprotective therapies in spinal cord injury; exploring biomedicines in behavioral neurology and neuropsychiatry; nanomaterials and its application in biomedicine; translational biomarkers in clinical biomedicine and precision medicine; G-protein-coupled receptor family; microbiota, probiotics, and nutraceuticals.

Guest Editors

Prof. Dr. Shaker A. Mousa

Dr. Zong Sheng Guo

Dr. Veronique Baud

Prof. Dr. Ciro Isidoro

Dr. Jacek M. Kwiecien

Prof. Ujendra Kumar

et al.



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/84863

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).